Skip to Content
Merck
All Photos(1)

Key Documents

Safety Information

SML2142

Sigma-Aldrich

Silodosin

≥98% (HPLC)

Synonym(s):

1-(3-Hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2­trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide, Rapaflo, Rapallo, Silodyx, Urief

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C25H32F3N3O4
CAS Number:
Molecular Weight:
495.53
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

NC(C1=CC(C[C@@H](C)NCCOC2=C(OCC(F)(F)F)C=CC=C2)=CC3=C1N(CCCO)CC3)=O

InChI

1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1

InChI key

PNCPYILNMDWPEY-QGZVFWFLSA-N

Biochem/physiol Actions

Silodosin is a selective alpha 1-adrenoceptor antagonist with high affinity for the ?1A adrenergic receptor, used clinically for the treatment of benign prostatic hyperplasia (BPH).

Pictograms

Health hazardExclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral - STOT RE 2

Target Organs

Liver

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

SML2142-10MG:
SML2142-VAR:
SML2142-BULK:
SML2142-50MG:


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hui Ding et al.
Renal failure, 38(9), 1311-1319 (2016-11-04)
To evaluate the efficacy of Silodosin as a medical expulsive therapy of ureteral stones, we searched PubMed, EMBASE, the Cochrane Library, and CBM up to June 2015. All randomized controlled trials (RCTs) were identified in which patients were randomized to
Takashi Yoshida et al.
Urology, 106, 153-159 (2017-04-23)
To evaluate the efficacy and safety of add-on therapy with the phosphodiesterase type 5 inhibitor tadalafil for patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH) treated with the α We analyzed 103 patients with LUTS/BPH with
Claus G Roehrborn et al.
Advances in therapy, 33(12), 2110-2121 (2016-11-05)
Available α1-blockers (ABs) have different profiles of receptor selectivity. Silodosin exhibits the highest selectivity for the α

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service